ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sarina Tanimoto Sells 100,000 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Sarina Tanimoto sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $9.62, for a total value of $962,000.00. Following the transaction, the insider now directly owns 1,496,494 shares in the company, valued at approximately $14,396,272.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Sarina Tanimoto also recently made the following trade(s):

• On Wednesday, June 12th, Sarina Tanimoto sold 95,862 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.15, for a total value of $877,137.30.
• On Thursday, May 16th, Sarina Tanimoto sold 89,096 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.06, for a total value of $807,209.76.
• On Tuesday, May 14th, Sarina Tanimoto sold 5,757 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.01, for a total value of $51,870.57.
• On Tuesday, May 7th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.34, for a total value of $934,000.00.
• On Tuesday, April 16th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.28, for a total value of $928,000.00.

ARS Pharmaceuticals Trading Up 6.2 %

Shares of NASDAQ SPRY traded up $0.65 during midday trading on Thursday, reaching $11.11. 944,199 shares of the company were exchanged, compared to its average volume of 591,892. ARS Pharmaceuticals, Inc. has a 1 year low of $2.55 and a 1 year high of $11.27. The stock has a fifty day simple moving average of $8.87 and a 200 day simple moving average of $8.12. The stock has a market cap of $1.08 billion, a P/E ratio of -21.21 and a beta of 0.87.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.11) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.11). As a group, analysts forecast that ARS Pharmaceuticals, Inc. will post -0.65 earnings per share for the current year.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in SPRY. Denali Advisors LLC purchased a new stake in ARS Pharmaceuticals in the 4th quarter valued at approximately $480,000. China Universal Asset Management Co. Ltd. boosted its holdings in ARS Pharmaceuticals by 352.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,105 shares of the company’s stock valued at $61,000 after purchasing an additional 8,652 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in ARS Pharmaceuticals by 22,300.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 5,600 shares of the company’s stock valued at $31,000 after purchasing an additional 5,575 shares in the last quarter. AJOVista LLC purchased a new stake in shares of ARS Pharmaceuticals during the 4th quarter worth approximately $43,000. Finally, Franklin Resources Inc. boosted its stake in shares of ARS Pharmaceuticals by 5.9% during the 4th quarter. Franklin Resources Inc. now owns 4,098,497 shares of the company’s stock worth $22,460,000 after acquiring an additional 229,988 shares in the last quarter. Hedge funds and other institutional investors own 68.16% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.